This funding commitment from JDRF will enable Cam Med to further the development of its innovative Evopump, an ultra-thin and flexible, bandage-like patch pump.

Since JDRF launched the Artificial Pancreas Project more than a decade ago, significant progress has been made in automating insulin delivery. 

However, the bulkiness of  automated insulin delivery devices remains a challenge and may be a factor inhibiting wide-scale adoption, especially in children where skin "real estate" is at a premium.

The goal of this collaboration is to accelerate the development of Cam Med's conformable and small-footprint Evopump, which would represent a substantial improvement over existing delivery systems for both pediatric and adult users.

JDRF research program scientist Dr Jaime Giraldo said: "JDRF is excited to partner with Cam Med on improving insulin delivery hardware. The Evopump represents the type of miniaturized and user-centric design that could substantially reduce the burden of living with type 1 diabetes and remove obstacles preventing some people, particularly children, from using devices that could improve their glucose management."

Cam Med CEO Larry Alberts said: “This partnership with JDRF enables Cam Med to accelerate the development and commercialization of the Evopump, and we're looking forward to it becoming the core delivery platform for future AP systems."

T1D is an autoimmune disease that occurs when a person's pancreas stops producing insulin, the hormone that controls blood-sugar levels. T1D develops when the insulin-producing pancreatic beta cells are mistakenly destroyed by the body's immune system. T1D must be managed with the lifelong use of insulin—either via injection or insulin pump.